Monte Carlo based water/medium stopping-power ratios for various ICRP and ICRU tissues

Towards the standardization of the absorbed dose report mode in high energy photon beams

The benefits of using an algorithm that reports absorbed dose-to-medium have been jeopardized by the clinical experience and the experimental protocols that have mainly relied on absorbed dose-to-water. The aim of the present work was to investigate the physical aspects that govern the dosimetry in heterogeneous media using Monte Carlo method and to introduce a formalism for the experimental validation of absorbed dose-to-medium reporting algorithms. Particle fluence spectra computed within the sensitive volume of two simulated detectors (T31016 Pinpoint 3D ionization chamber and EBT3 radiochromic film) placed in different media (water, RW3, lung and bone) were compared to those in the undisturbed media for 6 MV photon beams. A heterogeneity correction factor that takes into account the difference between the detector perturbation in medium and under reference conditions as well as the stopping-power ratios was then derived for all media using cema calculations. Furthermore, the different conversion approaches and Eclipse treatment planning system algorithms were compared against the Monte Carlo absorbed dose reports. The detectors electron fluence perturbation in RW3 and lung media were close to that in water (≤1.5%). However, the perturbation was greater in bone (∼4%) and impacted the spectral shape. It was emphasized that detectors readings should be corrected by the heterogeneity correction factor that ranged from 0.932 in bone to 0.985 in lung. Significant discrepancies were observed between all the absorbed dose reports and conversions, especially in bone (exceeding 10%) and to a lesser extent in RW3. Given the ongoing advances in dose calculation algorithms, it is essential to standardize the absorbed dose report mode with absorbed dose-to-medium as a favoured choice. It was concluded that a retrospective conversion should be avoided and switching from absorbed dose-to-water to absorbed dose-to-medium reporting algorithm should be carried out by a direct comparison of both algorithms.

A new dose quantity for evaluation and optimisation of MV photon dose distributions when using advanced algorithms: proof of concept and potential applications

Advanced algorithms used in MV photon radiotherapy model radiation transport in any media. They represent a step forward but introduce new uncertainties and questions, including whether to report the doses to water (D_w,m) or medium (D_m,m) voxels, and the impact of fluence changes introduced by surrounding media. These aspects can compromise consistency between both reporting modes and with previous algorithms in which clinical experience is based. This study introduces a new dose quantity, the dose-to-reference-like medium, to overcome the aforementioned shortcomings. It is linked to a reference medium, water in this study (D_w,m*), and defined as the absorbed dose in a voxel of this reference medium surrounded by a reference-like medium with the same radiation transport characteristics as the original one. We propose to derive D_w,m* distributions by post-processing D_w,m or D_m,m applying a correction factor (CF) to each voxel which depends on its composition. We present and justify a simple and straightforward method to obtain CFs that only involves two phantoms with the same density: one with the considered composition and the other with that of the reference medium. A proof of concept was performed in a clinical environment for Acuros XB (AXB) advanced algorithm and 6 MV photon beams. The CFs were derived for the tissues characterised in Acuros. D_w,m* was compared to D_w,m, D_m,m, and D_w,w from AAA analytical algorithm for some virtual and clinical cases. All the previous quantities presented limitations that can be solved by D_w,m*. This new quantity allows the applicability of evaluation parameters, traceability to clinical experience, and isolation of heterogeneity effects to identify optimum plans, offering useful characteristics for plan evaluation and optimisation in clinical practice. Additionally, it also has potential applications in automated treatment planning and multi-centre activities such as clinical trials, audits, benchmarking, and shared models for automation.

Monte Carlo Computation of Dose-Volume Histograms in Structures at Risk of an Eye Irradiated with Heterogeneous Ruthenium-106 Plaques

Background/Aims

The aim of this work is to compare Monte Carlo simulated absorbed dose distributions obtained from ¹⁰⁶Ru eye plaques, whose heterogeneous emitter distribution is known, with the common homogeneous approximation. The effect of these heterogeneities on segmented structures at risk is analyzed using an anthropomorphic phantom.

Methods

The generic CCA and CCB, with a homogeneous emitter map, and the specific CCA1364 and CCB1256 ¹⁰⁶Ru eye plaques are modeled with the Monte Carlo code PENELOPE. To compare the effect of the heterogeneities in the segmented volumes, cumulative dose-volume histograms are calculated for different rotations of the aforementioned plaques.

Results

For the cornea, the CCA with the equatorial placement yields the lowest absorbed dose rate while for the CCA1364 in the same placement the absorbed dose rate is 33% higher. The CCB1256 with the hot spot oriented towards the cornea yields the maximum dose rate per unit of activity while it is 44% lower for the CCB.

Conclusions

Dose calculations based on a homogeneous distribution of the emitter substance yield the lowest absorbed dose in the analyzed structures for all plaque placements. Treatment planning based on such calculations may result in an overdose of the structures at risk.

Large-scale dosimetric assessment of Monte Carlo recalculated doses for lung robotic stereotactic body radiation therapy

Owing to its short computation time and simplicity, the Ray-Tracing algorithm (RAT) has long been used to calculate dose distributions for the CyberKnife system. However, it is known that RAT fails to fully account for tissue heterogeneity and is therefore inaccurate in the lung. The aim of this study is to make a dosimetric assessment of 219 non-small cell lung cancer CyberKnife plans by recalculating their dose distributions using an independent Monte Carlo (MC) method. For plans initially calculated by RAT without heterogeneity corrections, target coverage was found to be significantly compromised when considering MC doses. Only 35.4% of plans were found to comply to their prescription doses. If the normal tissue dose limits were respected in the treatment planning dose, the MC recalculated dose did not exceed these limits in over 97% of the plans. Comparison of RAT and recalculated-MC doses confirmed the overestimation of RAT doses observed in previous studies. An inverse correlation between the RAT/MC dose ratio and the target size was also found to be statistically significant (p<10^-4), consistent with other studies. In addition, the inaccuracy and variability in target coverage incurred from dose calculations using RAT without heterogeneity corrections was demonstrated. On average, no clinically relevant differences were observed between MC-calculated dose-to-water and dose-to-medium for all tissues investigated (⩽1%). Patients receiving a dose D_95% larger than 119 Gy in EQD2₁₀ (or ≈52 Gy in 3 fractions) as recalculated by MC were observed to have significantly superior loco-regional progression-free survival rates (p=0.02) with a hazard ratio of 3.45 (95%CI: 1.14-10.5).

An EGS Monte Carlo model for Varian TrueBEAM treatment units: Commissioning and experimental validation of source parameters

In this work we have created and commissioned a Monte Carlo model of 6FFF Varian TrueBeam linear accelerator using BEAMnrc. For this purpose we have experimentally measured the focal spot size and shape of three Varian TrueBeam treatment units in 6FFF modality with a slit collimator and several depth dose and lateral beam profiles in a water phantom. The Monte Carlo model of a 6FFF TrueBeam machine was implemented with a primary electron source commissioned as a 2D Gaussian with Full Width Half Maximum selected by comparison of simulated and measured narrow beam profiles. The energy of the primary electron beam was optimized through a simultaneous fit to the measured beam depth dose profiles. Special attention was paid to evaluation of uncertainties of the selected Monte Carlo source parameters. These uncertainties were calculated by analysing the sensitivity of the commissioning process to changes in both primary beam size and energy. Both experimental and Monte Carlo commissioned focus size values were compared and found to be in excellent agreement. The commissioned Monte Carlo model reproduces within 1% accuracy the dose distributions of radiation field size from 3 cm × 3 cm to 15 cm × 15 cm.

The photon dose calculation algorithm used in breast radiotherapy has significant impact on the parameters of radiobiological models

The comparison of the pencil beam dose calculation algorithm with modified Batho heterogeneity correction (PBC-MB) and the analytical anisotropic algorithm (AAA) and the mutual comparison of advanced dose calculation algorithms used in breast radiotherapy have focused on the differences between the physical dose distributions. Studies on the radiobiological impact of the algorithm (both on the tumor control and the moderate breast fibrosis prediction) are lacking. We, therefore, investigated the radiobiological impact of the dose calculation algorithm in whole breast radiotherapy. The clinical dose distributions of 30 breast cancer patients, calculated with PBC-MB, were recalculated with fixed monitor units using more advanced algorithms: AAA and Acuros XB. For the latter, both dose reporting modes were used (i.e., dose-to-medium and dose-to-water). Next, the tumor control probability (TCP) and the normal tissue complication probability (NTCP) of each dose distribution were calculated with the Poisson model and with the relative seriality model, respectively. The endpoint for the NTCP calculation was moderate breast fibrosis five years post treatment. The differences were checked for significance with the paired t-test. The more advanced algorithms predicted a significantly lower TCP and NTCP of moderate breast fibrosis then found during the corresponding clinical follow-up study based on PBC calculations. The differences varied between 1% and 2.1% for the TCP and between 2.9% and 5.5% for the NTCP of moderate breast fibrosis. The significant differences were eliminated by determination of algorithm-specific model parameters using least square fitting. Application of the new parameters on a second group of 30 breast cancer patients proved their appropriateness. In this study, we assessed the impact of the dose calculation algorithms used in whole breast radiotherapy on the parameters of the radiobiological models. The radiobiological impact was eliminated by determination of algorithm specific model parameters.

Monte Carlo study for designing a dedicated "D"-shaped collimator used in the external beam radiotherapy of retinoblastoma patients

PURPOSE

Retinoblastoma is the most common intraocular malignancy in the early childhood. Patients treated with external beam radiotherapy respond very well to the treatment. However, owing to the genotype of children suffering hereditary retinoblastoma, the risk of secondary radio-induced malignancies is high. The University Hospital of Essen has successfully treated these patients on a daily basis during nearly 30 years using a dedicated "D"-shaped collimator. The use of this collimator that delivers a highly conformed small radiation field, gives very good results in the control of the primary tumor as well as in preserving visual function, while it avoids the devastating side effects of deformation of midface bones. The purpose of the present paper is to propose a modified version of the "D"-shaped collimator that reduces even further the irradiation field with the scope to reduce as well the risk of radio-induced secondary malignancies. Concurrently, the new dedicated "D"-shaped collimator must be easier to build and at the same time produces dose distributions that only differ on the field size with respect to the dose distributions obtained by the current collimator in use. The scope of the former requirement is to facilitate the employment of the authors' irradiation technique both at the authors' and at other hospitals. The fulfillment of the latter allows the authors to continue using the clinical experience gained in more than 30 years.

METHODS

The Monte Carlo code PENELOPE was used to study the effect that the different structural elements of the dedicated "D"-shaped collimator have on the absorbed dose distribution. To perform this study, the radiation transport through a Varian Clinac 2100 C/D operating at 6 MV was simulated in order to tally phase-space files which were then used as radiation sources to simulate the considered collimators and the subsequent dose distributions. With the knowledge gained in that study, a new, simpler, "D"-shaped collimator is proposed.

RESULTS

The proposed collimator delivers a dose distribution which is 2.4 cm wide along the inferior-superior direction of the eyeball. This width is 0.3 cm narrower than that of the dose distribution obtained with the collimator currently in clinical use. The other relevant characteristics of the dose distribution obtained with the new collimator, namely, depth doses at clinically relevant positions, penumbrae width, and shape of the lateral profiles, are statistically compatible with the results obtained for the collimator currently in use.

CONCLUSIONS

The smaller field size delivered by the proposed collimator still fully covers the planning target volume with at least 95% of the maximum dose at a depth of 2 cm and provides a safety margin of 0.2 cm, so ensuring an adequate treatment while reducing the irradiated volume.

PRIMO: a graphical environment for the Monte Carlo simulation of Varian and Elekta linacs

BACKGROUND

The accurate Monte Carlo simulation of a linac requires a detailed description of its geometry and the application of elaborate variance-reduction techniques for radiation transport. Both tasks entail a substantial coding effort and demand advanced knowledge of the intricacies of the Monte Carlo system being used.

METHODS

PRIMO, a new Monte Carlo system that allows the effortless simulation of most Varian and Elekta linacs, including their multileaf collimators and electron applicators, is introduced. PRIMO combines (1) accurate physics from the PENELOPE code, (2) dedicated variance-reduction techniques that significantly reduce the computation time, and (3) a user-friendly graphical interface with tools for the analysis of the generated data. PRIMO can tally dose distributions in phantoms and computerized tomographies, handle phase-space files in IAEA format, and import structures (planning target volumes, organs at risk) in the DICOM RT-STRUCT standard.

RESULTS

A prostate treatment, conformed with a high definition Millenium multileaf collimator (MLC 120HD) from a Varian Clinac 2100 C/D, is presented as an example. The computation of the dose distribution in 1.86×3.00×1.86 mm3 voxels with an average 2% standard statistical uncertainty, performed on an eight-core Intel Xeon at 2.67 GHz, took 1.8 h-excluding the patient-independent part of the linac, which required 3.8 h but it is simulated only once.

CONCLUSION

PRIMO is a self-contained user-friendly system that facilitates the Monte Carlo simulation of dose distributions produced by most currently available linacs. This opens the door for routine use of Monte Carlo in clinical research and quality assurance purposes. It is free software that can be downloaded from http://www.primoproject.net.

Development of a Geant4 based Monte Carlo Algorithm to evaluate the MONACO VMAT treatment accuracy

A method to evaluate the dosimetric accuracy of volumetric modulated arc therapy (VMAT) treatment plans, generated with the MONACO™ (version 3.0) treatment planning system in realistic CT-data with an independent Geant4 based dose calculation algorithm is presented. Therefore a model of an Elekta Synergy linear accelerator treatment head with an MLCi2 multileaf collimator was implemented in Geant4. The time dependent linear accelerator components were modeled by importing either logfiles of an actual plan delivery or a DICOM-RT plan sequence. Absolute dose calibration, depending on a reference measurement, was applied. The MONACO as well as the Geant4 treatment head model was commissioned with lateral profiles and depth dose curves of square fields in water and with film measurements in inhomogeneous phantoms. A VMAT treatment plan for a patient with a thoracic tumor and a VMAT treatment plan of a patient, who received treatment in the thoracic spine region including metallic implants, were used for evaluation. MONACO, as well as Geant4, depth dose curves and lateral profiles of square fields had a mean local gamma (2%, 2mm) tolerance criteria agreement of more than 95% for all fields. Film measurements in inhomogeneous phantoms with a global gamma of (3%, 3mm) showed a pass rate above 95% in all voxels receiving more than 25% of the maximum dose. A dose-volume-histogram comparison of the VMAT patient treatment plans showed mean deviations between Geant4 and MONACO of -0.2% (first patient) and 2.0% (second patient) for the PTVs and (0.5±1.0)% and (1.4±1.1)% for the organs at risk in relation to the prescription dose. The presented method can be used to validate VMAT dose distributions generated by a large number of small segments in regions with high electron density gradients. The MONACO dose distributions showed good agreement with Geant4 and film measurements within the simulation and measurement errors.

Monte Carlo calculation of dose distribution in early stage NSCLC patients planned for accelerated hypofractionated radiation therapy in the NCIC-BR25 protocol

The dosimetric consequences of plans optimized using a commercial treatment planning system (TPS) for hypofractionated radiation therapy are evaluated by re-calculating with Monte Carlo (MC). Planning guidelines were in strict accordance with the Canadian BR25 protocol which is similar to the RTOG 0236 and 0618 protocols in patient eligibility and total dose, but has a different hypofractionation schedule (60 Gy in 15 fractions versus 60 Gy in 3 fractions). A common requirement of the BR25 and RTOG protocols is that the dose must be calculated by the TPS without tissue heterogeneity (TH) corrections. Our results show that optimizing plans using the pencil beam algorithm with no TH corrections does not ensure that the BR25 planning constraint of 99% of the PTV receiving at least 95% of the prescription dose would be achieved as revealed by MC simulations. This is due to poor modelling of backscatter and lateral electronic equilibrium by the TPS. MC simulations showed that as little as 75% of the PTV was actually covered by the 95% isodose line. The under-dosage of the PTV was even more pronounced if plans were optimized with the TH correction applied. In the most extreme case, only 23% of the PTV was covered by the 95% isodose.